Medindia

X

Dexrazoxane Helps Prevent Chemotherapy-related Heart Damage in Children

by Sheela Philomena on  September 5, 2016 at 10:23 AM Drug News   - G J E 4
Dexrazoxane, a cardioprotective drug was found to prevent long-term heart damage in children receiving chemotherapy, reveals review published in the British Journal of Clinicial Pharmacology .
Dexrazoxane Helps Prevent Chemotherapy-related Heart Damage in Children
Dexrazoxane Helps Prevent Chemotherapy-related Heart Damage in Children
Advertisement

Advances in cancer therapy have significantly increased survival rates in children with cancer, but these survivors face increased long-term risks of experiencing side effects related to their treatment. For example, anthracyclines, which are among the most commonly used chemotherapeutic agents for treating children with cancer, are extremely effective, but they are also increase the risk of damage o the heart.

‘Dexrazoxane - cardioprotective medication should be considered as a part of therapy for young patients receiving chemotherapy treated with anthracyclines to prevent long-term heart damage.’
Advertisement
When Steven Lipshultz, MD, of Wayne State University School of Medicine and the Children's Hospital of Michigan, in Detroit, and his colleagues reviewed the medical literature, they found that anthracyclines can increase patients' risks of developing cardiomyopathy, heart failure, heart attacks, valve disease, pericardial disease, hypertension, and other cardiovascular-related conditions. The team also found that dexrazoxane has proven helpful in preventing many of the cardiotoxic effects of anthracycline treatment, without reducing its anticancer effects.

"Our review defines that the price of treatment for childhood cancer for many survivors is persistent, often progressive, and pervasive cardiotoxicity for those treated with anthracycline chemotherapy," said Dr. Lipshultz. "We then show that the accumulated data indicate that this chemotherapy-related heart damage can be ameliorated or prevented by the drug dexrazoxane when given immediately before each anthracycline dose." The findings indicate that the use of dexrazoxane can allow anthracyclines to be given more safely and at higher doses without risking damage to the heart.

The authors stressed that dexrazoxane should be considered as a part of therapy for young patients treated with anthracyclines. "If implemented, more children with cancer who are treated with anthracyclines may be cured of their malignancy and with less chemotherapy-associated toxicity and late effects," said Dr. Lipshultz.

Source: Eurekalert
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All